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Abstract
Targeting cannabinoid-2 (CB2) receptors with selective agonists may represent a novel therapeutic
avenue in various inflammatory diseases, but the mechanisms by which CB2 activation exerts its
anti-inflammatory effects and the cellular targets are elusive. Here, we investigated the effects of
CB2-receptor activation on TNF-α-induced signal transduction in human coronary artery endothelial
cells in vitro and on endotoxin-induced vascular inflammatory response in vivo. TNF-α induced NF-
κB and RhoA activation and upregulation of adhesion molecules ICAM-1 and VCAM-1, increased
expression of monocyte chemoattractant protein, enhanced transendothelial migration of monocytes,
and augmented monocyte-endothelial adhesion. Remarkably, all of the above-mentioned effects of
TNF-α were attenuated by CB2 agonists. CB2 agonists also decreased the TNF-α- and/or endotoxin-
induced ICAM-1 and VCAM-1 expression in isolated aortas and the adhesion of monocytes to aortic
vascular endothelium. CB1 and CB2 receptors were detectable in human coronary artery endothelial
cells by Western blotting, RT-PCR, real-time PCR, and immunofluorescence staining. Because the
above-mentioned TNF-α-induced phenotypic changes are critical in the initiation and progression
of atherosclerosis and restenosis, our findings suggest that targeting CB2 receptors on endothelial
cells may offer a novel approach in the treatment of these pathologies.
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Atherosclerosis is the leading cause of common cardiovascular disorders such as coronary
artery disease, stroke, and various forms of heart failure, abdominal aortic aneurysms, and
ischemic gangrene, which are the principal causes of death in Western countries. Recent studies
have revealed important cross-talk between inflammation, generation of reactive oxygen,
nitrogen species, and lipid metabolism in the pathogenesis of atherosclerosis and vascular
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remodeling following injury (10,12,30,31). Bacterial endotoxin(s) and proinflammatory
cytokines (e.g., TNF-α), which mediate, at least in part, their proatherogenic effects by eliciting
NF-κB activation in endothelial cells (17,21,24,39,48,50), are considered to play pivotal roles
in vascular inflammation associated with atherosclerosis and development of coronary arterial
disease (4,20,23,27,35,39,43,44). The activation of this pathway leads to induction of adhesion
molecules and chemokines, e.g., VCAM-1, ICAM-1 (48), which promote monocyte
adhesiveness to the endothelium, and the release of a variety of factors that promote smooth
muscle migration and proliferation (from the medium into the intima), which then synthesize
and deposit extracellular matrix (10,14,28). There is considerable evidence suggesting that
disruption of the cytokine-induced NF-κB signaling pathway confers significant
vasculoprotective effects by attenuating vascular inflammation (24,36), which delays or
prevents atherogenesis in animal models (4,18,42) of disease.
To date, two cannabinoid (CB) receptors have been identified by molecular cloning: the CB1
receptor, which is highly expressed in the brain but is also present in peripheral tissues including
the heart, vascular tissues, and liver, and the CB2 receptor, previously thought to be expressed
predominantly by immune and hematopoietic cells (reviewed in Refs. 22,29). However, more
recent studies have also demonstrated CB2 receptors in brain (45), myocardium (26),
cardiomyoblasts (26,34), and endothelial cells of various origins (3,9,25,52) (reviewed in Refs.
19,29).
The natural ligands of these receptors are lipid-like substances called endocannabinoids, which
include arachidonoyl ethanolamide or anandamide and 2-arachidonoylglycerol (22,29).
Endocannabinoids and their synthetic analogs exert various central nervous system,
cardiovascular, and anti-inflammatory effects through CB1 and CB2 receptors (19,29).
A recent study has demonstrated that orally administered cannabis constituent Δ9-
tetrahydrocannabinol, which is a mixed weak CB1/2-receptor agonist with psychoactive
property, inhibited atherosclerosis progression in a mouse model of disease, an effect that could
be blocked by a selective CB2-receptor antagonist (38). However, the role of CB2 receptor in
vascular endothelial cell activation and inflammatory response is still unexplored.
Herein, we evaluated the effects of CB2-receptor activation on TNF-α-induced NF-κB and
RhoA activation, upregulation of adhesion molecules ICAM-1 and VCAM-1, expression of
monocyte chemoattractant protein in human coronary artery endothelial cells (HCAECs),
transendothelial migration (TEM) of monocytes, monocyte-endothelial adhesion in vitro, and
endotoxin-induced vascular inflammatory response in vivo. Because these pathological events
are pivotal in the initiation and progression of atherosclerosis and restenosis, our findings may
have important clinical implications and underscore the role of CB2 receptors as a novel
therapeutic target in various vascular diseases associated with inflammation.
MATERIALS AND METHODS
Materials
The selective CB2 receptor agonist JWH-133 was either purchased from Tocris Bioscience
(Ellisville, MO) or synthesized as described earlier (13). The selective CB2-receptor agonist
HU-308 (11) was from Cayman Europe (Tallinn, Estonia). The CB1-receptor antagonist
AM-281 and CB2-receptor antagonist AM-630 were purchased from Tocris Bioscience
(Ellisville, MO). The CB1 antagonist SR-141716A and CB2 antagonist SR-144528 were from
NIDA Drug Supply (Research Triangle Park, NC). Human recombinant TNF-α was obtained
from R&D Systems. Sources of all the other reagents are mentioned in the text where
appropriate.
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Cell Culture
HCAECs and the growth medium were purchased from Cell Applications (San Diego, CA).
The human monocytic cell line THP-1 was obtained from American Type Culture Collection;
cells were grown in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10 mM
HEPES, 10% FBS, 100 U of penicillin, and 100 μg of streptomycin/ml (Invitrogen).
CB1 and CB2 Expression in HCAECs
Immunofluorescence staining—CB1 expression and CB2 expression in the human
endothelial cells were determined by immunofluorescence staining technique. In brief,
HCAECs were grown to confluence in chamber slides (Nalgene-Nunc, Lab-Tek). Growth
medium was aspirated, and cells were washed three times with PBS and then fixed with 4.0%
paraformaldehye for 20 min at 4°C. After cells were washed with PBS, cells were
permeabilized with 0.2% Triton X-100 in PBS for 15 min at room temperature. Subsequently,
CB1 expression and CB2 expression in the human endothelial cells were determined by
immunofluorescence staining technique using anti-CB1 (rabbit polyclonal; Cayman Chemical)
or anti-CB2 (rabbit polyclonal; Cayman Chemical), respectively, used at 1:100 dilution for 6
h at 4°C. After the cells were rinsed with PBS, the cells were probed with goat anti-rabbit FITC
(1:250; Pierce) for 1 h at room temperature. The nucleus was counterstained with 4′,6-
diamidino-2-phenylindole (Molecular Probes). Images were obtained with a fluorescent
microscope (Olympus IX 81) at ×20 objective with ×1.5 optical zoom. To rule out the
nonspecific staining, we used the corresponding blocking peptides for CB1 (catalog no.
10006591, Cayman Chemical) or CB2 (catalog no. 301550, Cayman Chemical). In brief, the
blocking peptides were mixed with corresponding antibodies in a 1:1 ratio and incubated for
1 h at room temperature. This preabsorbed antibody was then used for the staining process.
This procedure essentially blocks the antibody-antigen (protein) formation during the
immunofluorescence staining and aids in determining the specificity of the staining.
Conventional RT-PCR and quantitative real-time RT-PCR—Total RNA was isolated
from the cells using Trizol LS reagent (Invitrogen) according to manufacturer’s instruction.
The RNA was treated with RNase-free DNase (Ambion) to remove traces of genomic DNA
contamination. Total RNA was then reverse transcribed to cDNA using SuperScript II
(Invitrogen), and the target genes were amplified with the standard PCR kit (Bio-Rad). The
PCR conditions were as follows: after initial denaturation at 95°C for 2 min, 35 cycles were
performed at 95°C for 30 s and at 60°C for 30s. Primers used were as follows: for CB1, 5′-
TTCCCTCTTGTGAAGGCACTG-3′ (forward) and 5′-TCTTGACCGTGCTCTTGATGC-3′
(reverse); for CB2, 5′-TTTGCTTTCTGCTCCATGCTG-3′ (forward) and 5′-TTCTTTT-
GCCTCTGACCCAAG-3′ (reverse); for β-actin, 5′-ATTGCCGA-CAGGATGCAGAAG-3′
(forward) and 5′-TAGAAGCATTTGCG-GTGGACG-3′ (reverse).
The amplified products were separated on 1.5% agarose gels, stained with ethidium bromide,
and documented using the Typhoon system (GE Healthcare).
In a separate set of experiments, real-time PCR was performed in identical conditions, except
amplification and quantification of the target gene expression were performed with the iTaq
Sybr green mix (Bio-Rad) and Bio-Rad chromo4/opticon system (data not shown). Relative
quantification was performed with the relative comparative threshold (CT) method.
Western immunoblot assay—HCAECs were grown to confluence in 100-mm culture
dishes coated with 0.2% gelatin. Cells were suspended in RIPA lysis buffer (Pierce)
supplemented with protease inhibitors (Roche). Cell lysates were then prepared by sonication
15k for 20 s) on ice. The lysates then were clarified to remove the cellular debris by centrifuging
at 10,000 rpm for 15 min at 4°C. Protein content in the lysates was determined with the Lowry
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assay (Bio-Rad). Protein (30 μg) was resolved in 12% SDS-PAGE and transferred to
nitrocellulose membranes (GE Healthcare). Blocking was performed for 2 h at room
temperature with 5% nonfat skimmed milk powder prepared in PBS containing 0.1% Tween
20 (PBST; Sigma). After they were washed with PBST, membranes were probed with either
rabbit polyclonal CB1 (Cayman Chemical; 1:1,000 dilution or an antibody raised against the
last 15 residues of rat CB1) or CB2 antibody (Cayman Chemical; 1:1,000 dilution) overnight
at 4°C. After a subsequent washing with PBST, the secondary antibody goat anti-rabbit
horseradish peroxidase (Pierce) and incubated at room temperature for 1 h. The membranes
were then developed using chemiluminescence detection kit (SuperSignal-west Pico substrate,
Pierce). To confirm uniform loading, membranes were stripped and reprobed with β-actin
(Chemicon). Proteins from mouse brain extract and human monocytic cell line (THP-1) lysate
were used as appropriate positive controls for CB1 and CB2 receptors, respectively.
Cell Surface ICAM-1 and VCAM-1 Expression Assay
Cell surface expression of ICAM-1 and VCAM-1 was measured by in situ ELISA as described
(2). In brief, HCAECs were grown in 96-well plates coated with 0.2% gelatin. After treatments,
in situ ELISA was performed with anti-human ICAM-1 or VCAM-1 monoclonal antibodies
(1:1,500 dilution; R&D Systems) and by measuring the absorbance at colorimetrically at 450
nm using the horseradish peroxidase-3,3′,5,5′-tetramethylbenzidine developing system
(Sigma). Each treatment was performed in triplicate, and the experiments were repeated three
times.
Monocyte-Endothelial Cell Adhesion Assay
Monocyte adhesion to endothelial cells was performed as described with modifications (47).
In brief, HCAECs were grown to confluence in 24-well plates and treated with TNF-α ±
CB2 agonists/antagonists. THP-1 monocytes were then labeled with 1.5 μM calcein-AM
(Molecular Probes-Invitrogen) for 1 h at 37°C in RPMI 1640 containing 1% FBS. HCAECs
were washed twice with HCAEC basal medium and incubated with 400 μl of basal medium.
Then 105 cells/100 μl of labeled THP-1 cells were overlaid on HCAECs and incubated for 1
h at 37°C. After incubation, the monolayer was carefully washed with PBS to remove the
unbound monocytes. The adherent monocytes to the endothelial cells were documented with
an Olympus IX 81 fluorescent microscope using ×10 objective with ×1.5 optical zoom.
Individual treatments were preformed in duplicate, and the entire set of experiments was
repeated at least three times.
Monocyte Chemoattractant Protein-1 Expression
Levels of monocyte chemoattractant protein-1 (MCP-1) expression in the HCAECs were
determined using an ELISA kit (R&D Systems).
Monocyte Transendothelial Migration Assay
HCAECs were allowed to reach confluence on 0.2% gelatin-coated 3.0-μm polyethylene
terepthalate track-etched cell culture inserts (BD Biosciences). TEM assays were then
performed essentially as described with modifications (5). In brief, THP-1 cells were labeled
with 2 μM Cell Tracker green 5-chloromethylfluorescein diacetate (Molecular Probes).
Labeled THP-1 cells (3 × 105/200 μl) were added to the upper compartment of the cell culture
insert, and the lower compartment of the insert contained 0.5 ml serum-free RPMI 1640. The
monocytes were then allowed to transmigrate for 4 h at 37°C in 5% CO2 incubator. After
incubation, fluorescence at the lower chamber was measured with the Victor-Wallac Multilabel
counter (Perkin Elmer) at excitation of 492 nm and emission of 571 nm. Each treatment was
performed in duplicate, and experiment sets were repeated two times. The monocyte TEM was
expressed as percent cell migrated.
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RhoA Activation Assay
Rho activation in HCAECs was performed with commercially available kits (Pierce). In brief,
RhoA activation assay was performed by pull-down assay, with Rhotekin-Rho binding domain
fused with glutathione S-transferase. The active or GTP-RhoA pulled down from the cell
lysates was analyzed by Western blot assays using anti-Rho antibody.
NF-κB Activation
NF-κB activation by TNF-α and the effect of CB2 agonists/antagonists were analyzed by
Western imunoblot and immunofluorescence assays, respectively.
In Vivo Vascular Inflammation Model
Protocols involving the use of experimental animals were approved by the author’s institutional
animal care and use committee and were performed in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals. Male C57Bl/6J mice (6–8 wk)
were administered 3 mg/kg LPS (E. coli serotype O197:B8; Sigma) in a single intraperitoneal
dose. In some experiments, 1 h before LPS administration, experimental animals were injected
with HU-308 or JWH-133 (10 mg/kg ip) ± AM-630 (3 mg/kg ip). After 4 h, animals were
euthanized, and aortas were dissected and snap frozen for the determination of ICAM-1 and
VCAM-1 expressions.
Monocyte Adhesion to Aortic Vascular Endothelium
Monocyte-enriched peripheral blood mononuclear cells were isolated from rats, and binding
of BCECF-labeled (5 μmol/l final concentration; Molecular Probes) monocytes to the vascular
endothelium was determined as previously described (6). In brief, rat aortic segments were
treated with HU-308 or JWH-133 (3 μM) ± AM-630 (1 μM) ± TNF-α (50 ng/ml, for 4 h). The
vessels were cut open (en face preparation) and incubated with BCECF-loaded monocytes.
After a 1-h incubation at 37°C, unbound monocytes were washed out. Bound monocytes were
quantified by counting the cells under a fluorescent microscope. Representative images were
captured using a fluorescent microscope (Olympus IX 81; original magnification: ×10;
endothelial cell’s nuclei were counterstained with Hoechst 33258 for orientation).
In another set of experiments, rats were injected with a single dose of LPS (3 mg/kg ip) with
or without the pretreatment with HU-308 or JWH-133 (10 mg/kg) ± AM-630 (3 mg/kg) for 1
h; 6 h later aortas were isolated, and monocyte adhesion to vascular endothelium was
performed. Monocyte adhesion to the vascular endothelium was then determined as described
in the previous paragraph.
Statistical Analysis
All values are means ± SE. Statistical significance of the data was assessed by one-way
ANOVA with Tukey’s post hoc test (GraphPad-Prism4). P < 0.05 was considered significant.
RESULTS
CB1 and CB2 Receptors Are Expressed in HCAECs
As shown in Figs. 1 and 2, CB1 and CB2 receptors are expressed in endothelial cells, at basal
conditions as demonstrated by immunofluorescence assays (Fig. 1A), conventional RT-PCR
(Fig. 1, B and C), and Western blot (Fig. 1, D and E). From quantitative analysis of Western
blot, it was revealed that mice brain extracts had ~4.5-fold increased CB1-receptor expression
compared with HCAECs (Fig. 1D). CB2 expression was ~5.5-fold higher in THP-1 monocytes
than in HCAECs (Fig. 1E). Protein from mouse brain extracts and THP-1 cell lysates were
used as appropriate positive controls for CB1 and CB2 receptors, respectively. To rule out the
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nonspecific staining for CB1 or CB2 expression, we preabsorbed either CB1 or CB2 with the
corresponding blocking peptides supplied with the primary antibodies. Next, we used the
preabsorbed anti-body for the detection of CB1 and CB2 in HCAECs simultaneously with the
neat antibodies. Our results indicated that preabsorbed antibodies failed to stain the CB1 or
CB2 receptors in HCAECs, suggesting that the antibody specifically recognizes CB1 or CB2
receptors in HCAECs (Fig. 1A). Similar results were obtained with Western blot assays (data
not shown).
CB2 Agonists Inhibit TNF-α-Induced ICAM-1 and VCAM-1 Expression In Vitro
TNF-α (50 ng/ml) treatment of HCAECs for 6 h, resulted in marked upregulation of ICAM-1
and VCAM-1 expressions, which were dose dependently diminished by HU-308 or JWH-133
(Fig. 2, A and B). These effects of CB2 agonists were attenuated by CB2 (SR-144528 and
AM-630) but not by CB1 (SR-141716 and AM-251) antagonists (Fig. 2, C and D). CB1 or
CB2 antagonists by themselves had no effect on TNF-α-induced adhesion molecule expression
(Fig. 2, C and D).
CB2 Agonists Attenuate TNF-α-Induced Monocyte Adhesion and MCP-1 Expression In Vitro
and Ex Vivo
Pretreatment of HCAECs with HU-308 or JWH-133 (3 μM) from 1 h before and during the
complete TNF-α exposure inhibited TNF-α-induced monocyte adhesion (Fig. 3, A and B) and
MCP-1 expression (Fig. 3C), and these effects were attenuated by CB2 antagonists (Fig. 3).
HU-308 also inhibited TNF-α-induced monocyte adhesion in aortas ex vivo (Fig. 4A).
CB2 Agonists Attenuate Endotoxin (LPS)-Induced ICAM-1 and VCAM-1 Expression In Vivo
and Adhesion of Monocytes to the Aortic Segments
Endotoxin administration to mice has been shown to induce massive vascular inflammation
and characterized by increase in adhesion molecules and NF-κB activation (40,51). Because
in vitro CB2-receptor stimulation blunted cytokine-induced adhesion molecule expression and
NF-κB activation, we tested whether CB2-receptor stimulation could ameliorate LPS-induced
vascular inflammation in vivo. We found that LPS administration markedly induced ICAM-1
and VCAM-1 (Fig. 4B) expression in the aortas (~5.6- and 4.8-fold increase compared with
mice treated with vehicle alone). HU-308 or JWH-133 pretreatment markedly reduced the
expression of both ICAM-1 and VCAM-1 (Fig. 4B), which could be attenuated by the CB2
antagonist AM-630.
CB2 agonist HU-308 also significantly inhibited monocyte adhesion to the aortic segments
prepared from rats treated with LPS (Fig. 4C). This effect was attenuated by CB2 antagonist
AM-630 (Fig. 4C), suggesting that CB2-receptor activation could mitigate the endotoxin-
induced vascular inflammation.
CB2 Agonists Inhibit TNF-α-Induced Monocyte TEM and RhoA Activation in HCAECs
TNF-α treatment of HCAECs markedly increased monocyte TEM ~4–3 fold vs. control. This
was attenuated by HU-308 or JWH-133 (3 μM; Fig. 5A). Furthermore, TNF-α treatment
induced RhoA activation (~4.0-fold vs. control), and this activation was attenuated by treatment
with HU-308 or JWH-133 (Fig. 5B). These effects of CB2 agonists were attenuated by CB2
antagonist.
CB2 Agonists Decrease TNF-α-Induced NF-κB Activation in HCAECs
TNF-α treatment leads to marked NF-κB activation, characterized by increased translocation
to the nucleus as demonstrated by Western blot (Fig. 6A). We observed ~2.5-fold increase in
nuclear translocation of p65 (NF-κB) (Fig. 6A); likewise, a marked increase in
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immunofluorescence was also observed above the nuclei of cells treated with TNF-α (Fig.
6B). These effects were significantly decreased by the pretreatment with HU-308 or JWH-133,
and the latter could be attenuated by CB2-antagonist AM-630.
DISCUSSION
The novel and definitive findings emerging from our study is that HCAECs express both
CB1 and CB2 receptors under basal/physiological conditions. Importantly, our study also
demonstrates that CB2-receptor activation attenuates TNF-α-triggered NF-κB and RhoA
activation, upregulation of adhesion molecules ICAM-1 and VCAM-1, expression of
monocyte chemoattractant protein, TEM of monocytic THP-1 cells, and monocyte-endothelial
adhesion in HCAECs. Furthermore, CB2-receptor activation attenuates TNF-α-induced
adhesion of monocytes to aortic endothelium ex vivo, the endotoxin-induced ICAM-1 and
VCAM-1 expression and adhesion of monocytes to aortic endothelium of isolated aortas of
endotoxin-treated rats.
Presently, it is thought that CB1 receptors are primarily expressed in the brain and some
peripheral tissues, including the heart, vascular tissues, adipocytes, and liver (22,29). On the
other hand, the CB2 receptor was previously considered to be expressed predominantly by
immune and hematopoietic cells (22,29). However, more recent studies have also found CB2
receptors in brain (45), myocardium (26), cardiomyoblasts (26,34), and endothelial cells of
various origins (3,9,25,52). Here, we report expression of CB1 and CB2 receptors in HCAECs
under basal/physiological conditions. Interestingly, the expression of CB2 receptors could be
enhanced by the proinflammatory cytokine TNF-α in endothelial cells (data not shown). A
similar phenomenon was previously proposed during the microglia activation (46).
The hallmark for the development of atherosclerosis is the adhesion of monocytes to the
endothelium, followed by TEM of monocytes (10). It has been well-established that TNF-α
and/or endotoxin(s) induces NF-κB-dependent upregulation of the expression of ICAM-1,
VCAM-1, and MCP-1 in endothelial cells, contributing to the increased adhesion of monocytes
to the endothelium migration and TEM (43). The TNF-α-induced NF-κB activation has been
shown to involve RhoA activation (21), and RhoA activation was also implicated in monocyte
TEM (33). Likewise, MCP-1 has been shown to be involved in monocyte TEM (41) and
endothelial barrier disruption through RhoA activation (37). Consistent with the above-
mentioned studies, we found that TNF-α increased NF-κB and RhoA activation, upregulation
of adhesion molecules ICAM-1 and VCAM-1, expression of MCP-1, monocyte-endothelial
adhesion in HCAECs, and TEM of monocytes. We demonstrate that selective CB2-receptor
agonists JWH-133 and HU-308 markedly decrease TNF-α-increased NF-κB activation,
upregulation of adhesion molecules ICAM-1 and VCAM-1, expression of MCP-1, monocyte-
endothelial adhesion in HCAECs, and TEM of monocytic THP-1 cells in a CB2-dependent
manner, since these effects of CB2 agonists could be attenuated by CB2 antagonists. Consistent
with our observation, it has been recently demonstrated that JWH-015, another less potent
CB2 agonist inhibited the TEM of T lymphocytes stimulated by chemokines such as CXCL12
and CXCR4 (8).
Adhesion molecules also mediate the initial attachment of neutrophils to the activated
endothelium, which is a crucial early event in ischemia-reperfusion injury (15,16). On
reperfusion, inflammatory cytokines (e.g., TNF-α) act as continuous stimuli for neutrophil
infiltration and upregulate the production of chemokines, which may also contribute to the
upregulation of cell adhesion molecules and neutrophil activation (15,16). Numerous recent
studies have demonstrated that CB2-receptor activation may also protect against myocardial
(7), cerebral (49), and hepatic ischemia-reperfusion (1,32) injuries by decreasing the
endothelial cell activation, the expression of adhesion molecules ICAM-1 and VCAM-1, TNF-
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α, and chemokine (MIP-1α and MIP-2) levels, neutrophil infiltration, lipid peroxidation, and
apoptosis.
Collectively, our results suggest that selective CB2-receptor agonists may offer a novel
approach in the treatment of a variety of inflammatory diseases, including atherosclerosis. Thus
attenuation of TNF signaling, coupled with the absence of psychoactive effects associated with
CB2-receptor stimulation, makes this a particularly encouraging therapeutic approach.
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Fig. 1.
Cannabinoid-1 (CB1) and cannabinoid-2 (CB2) receptors are expressed in human coronary
artery endothelial cells (HCAECs). A: expression of CB1 and CB2 receptors in HCAECs
demonstrated by immunofluorescence staining. CB1 expression and CB2 expression in the
endothelial cells were detected with rabbit polyclonal anti-CB1 and anti-CB2 antibodies
(Cayman Chemical) and detected by secondary antibody goat anti-rabbit FITC (Pierce); the
nucleus was counterstained with 4′,6-diamidino-2-phenylindole (Molecular Probes,
Invitrogen). B and C: RT-PCR analysis of CB1 (B) and CB2 (C) receptor expression in
endothelial cells. D and E, left: Western immunoblot demonstrating expression of CB1 (D) and
CB2 (E) in endothelial cells. Six samples from 3–5 passages from HCAECs or THP-1 and
lysates from six brain tissues from wild-type C57Bl/6J mice were used to evaluate CB1 and
CB2 expression in human endothelial cells. D and E, right: the quantification of CB1 and
CB2 expression in HCAECs; n = 6 samples. *P < 0.05 vs. brain extract or THP-1 cells.
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Fig. 2.
CB2 agonists decrease TNF-α-induced ICAM-1 and VCAM-1 expression in HCAECs. A and
B: ICAM-1 (A) and VCAM-1 (B) expression. Cells were treated with either TNF-α or CB2
agonists for 6 h or with CB2 agonists with the indicated concentrations followed by treatment
with TNF-α for 6 h. Cell surface ELISA was then performed by measuring the absorbance at
450 nm as described in MATERIALS AND METHODS to determine cell surface ICAM-1 or
VCAM-1 expression; n = 9 samples. *P < 0.05 vs. control; #P < 0.05 vs. TNF-α. C and D:
cells were pretreated with CB1 or CB2 antagonists followed by treatment with TNF-α ± CB2
agonists as indicated for 6 h or pretreated with CB1 or CB2 antagonists (1 μM each) followed
by treatment with either TNF-α alone or in combination with CB2 agonists. Cell surface ELISA
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was then performed; n = 9 samples. OD, optical density. *P < 0.05 vs. control; #P < 0.05 vs.
TNF-α; †P < 0.05 vs. TNF-α + HU-308 or JWH-133.
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Fig. 3.
CB2 agonists decrease TNF-α-induced monocyte chemoattractant protein-1 (MCP-1)
expression in HCAECs and monocyte adhesion to HCAECs. SR2, SR-144528; T, TNF-α. A:
representative fields of monocytes adhered to HCAECs with representative treatments as
indicated. B: quantification of data for monocyte adherence to endothelial cells when incubated
with TNF-α ± HU-308 or JWH-133 (4 μM) for 6 h or pretreated with CB2 antagonists (1 μM)
for 1 h followed by treatment with TNF-α ± HU-308 or JWH-133 for 6 h; n = 9 samples. *P
< 0.05 vs. control; #P < 0.05 vs. TNF-α; †P < 0.05 vs. TNF-α + HU-308 or JWH-133. C:
MCP-1 expression in HCAECs for treatments indicated; n = 6 samples. *P < 0.05 vs. control;
#P < 0.05 vs. TNF-α; †P < 0.05 vs. TNF-α + HU-308 or JWH-133.
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Fig. 4.
CB2 agonists mitigate TNF-α- and/or endotoxin (LPS)-induced ICAM-1 and VCAM-1
expression and monocyte adhesion to aortic endothelium of rats ex vivo or in vivo. A: CB2
agonist HU-308 mitigates adhesion of monocytes to aortic vascular endothelium of isolated
aortas pretreated with TNF-α; n = 4 samples. *P < 0.05 vs. vehicle [control (Co)]; #P < 0.05
vs. TNF-α; †P < 0.05 vs. LPS + HU-308 or JWH-133. B: mice were treated with LPS ± HU-308
or JWH-133 ± AM-630 as indicated; n = 6 samples. Aortas were then isolated, and ICAM-1
or VCAM-1 expressions were determined by ELISA (R&D Systems).*P < 0.05 vs. vehicle-
treated (Co) mice; #P < 0.05 vs. LPS; †P < 0.05 vs. LPS + HU-308 or JWH-133. Protein
estimation in the tissue lysates was determined by Lowry assay (Bio-Rad). Values are
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expressed as ng/mg protein. C: CB2 agonist HU-308 mitigates endotoxin-induced monocyte
adhesion to aortic vascular endothelium of isolated aortas of rats treated with endotoxin; n =
4 samples. *P < 0.05 vs. vehicle-treated (Co) mice; #P < 0.05 vs. LPS-treated rats; †P < 0.05
vs. LPS + HU-308 or JWH-133.
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Fig. 5.
CB2 agonists decrease TNF-α-induced monocyte transendothelial migration (TEM) and RhoA
activation in HCAECs. A: HCAECs were treated as indicated, and then monocyte TEM assays
were performed as described in MATERIALS AND METHODS; n = 4 samples. *P < 0.05
vs. controls; #P < 0.05 vs. TNF-α; †P < 0.05 vs. TNF-α + HU-308 or JWH-133. B: HCAECs
were grown in 100-mm culture dishes and treated in identical manner as described above, 500
μg cell lysates were incubated with Rhotekin-Rho binding domain-glutathione S-transferase
fusion protein, and pull-down assays were performed (Pierce), with active RhoA detected with
the use of anti-RhoA antibody; n = 3 samples. *P < 0.05 vs. controls; #P < 0.05 vs. TNF-α;
†P < 0.05 vs. TNF-α + HU-308 or JWH-133.
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Fig. 6.
CB2 agonists decrease TNF-α-induced NF-κB activation in HCAECs. A: cells were treated
with TNF-α ± HU-308 or JWH-133 (3 μM) for 6 h or pretreated with CB2 antagonists (1 μM)
followed by treatment with TNF-α ± HU-308 or JWH-133 for 6 h. Nuclear extracts were then
prepared, and NF-κB expression was determined by Western immunoblot assay; n = 3 samples.
*P < 0.05 vs. control; #P < 0.05 vs. TNF-α; †P < 0.05 vs. TNF-α + HU-308 or JWH-133. B:
activation of NF-κB by TNF-α in HCAECs, and CB2 agonists inhibit NF-κB activation. Note
the intense nuclear staining of NF-κB (p65) in cells exposed to TNF-α and the faint staining
indicating that CB2 agonists diminished TNF-α activation of NF-κB. Shown are representative
images from 3 separate experiments.
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